Welcome to Celon Pharma S.A.

Celon Pharma S.A. is an integrated pharmaceutical company which conducts advanced research and manufactures modern drugs. The company is also a successful marketing authorisation holder for it products. The drugs we offer help thousands of patients lead a better and longer life.

News

• Strong Proof-of-Concept Data from Phase 2 Trial of PDE10A Inhibitor (CPL’36), a Novel Oral Antipsychotic9 July 2024
• Current report 17/2024 – Positive Phase II top – line results for CPL’ 36, a PDE10A inhibitor in the treatment of acute schizophrenia5 July 2024
  In reference to current report No. 26/2020 of September 30, 2020 on obtaining consent to start a Phase II clinical trial on a drug based on CPL'36, an innovative PDE10ARead more »
• Current report 11/2024 – Results of phase II clinical trial for CPL’ 116, a JAK/ROCK dual inhibitor in the treatment of Rheumatoid Arthritis (RA)17 June 2024
  In reference to current reports 36/2021 on the successful completion of phase I clinical trial and 47/2021 on submission of an application for consent to commence a phase II trialRead more »

Research and development

Products